莲池医院冲击港股IPO，有望成“山东民营医院第一股”

Core Viewpoint - Lianchi Hospital Group Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with China Galaxy International as the joint sponsor, aiming to expand its specialized medical services in China [3]. Company Overview - Lianchi Hospital is a Chinese boutique specialized medical group that emphasizes a patient-centered approach and operates five hospitals and one elderly care facility by September 30, 2025 [4]. - The company focuses on the "One Elderly, One Child" high-potential sector, aligning with the national "Healthy China" strategy [4]. - Lianchi Hospital has established a well-defined hospital network, including Zibo Lianchi Hospital, Qingdao Lianchi Maternal and Child Hospital, Hefei Xinhai Maternal and Child Hospital, Zibo Lianchi Orthopedic Hospital, and Chongqing Great Wall Orthopedic Hospital [4][5]. Competitive Position - Each hospital within the Lianchi Hospital Group holds a unique competitive advantage and enjoys a prominent market position in their respective regions [5]. - Zibo Lianchi Hospital is recognized as a second-level hospital and has been awarded various local health education and service quality recognitions [5]. - Qingdao Lianchi Maternal and Child Hospital is the first private hospital in Qingdao to receive international JCI certification [6]. - Chongqing Great Wall Orthopedic Hospital is recognized as a leading private orthopedic hospital in Southwest China based on revenue [7]. Financial Performance - The company has shown significant revenue growth, with revenue increasing from RMB 356 million in 2023 to RMB 418 million in 2024, representing a 17.4% growth [10]. - For the nine months ending September 30, 2025, revenue further increased by 20.3% to RMB 359 million compared to the same period in 2024 [10]. - The gross profit margin improved from 32.9% in 2023 to 36.1% in 2024, with a slight decrease to 35.6% for the nine months ending September 30, 2025 [10]. - Net profit rose from RMB 56.7 million in 2023 to RMB 67.6 million in 2024, marking a 19.2% increase [11]. Market Demand - The aging population in Shandong and Chongqing provinces is driving the demand for orthopedic services [11]. - The private orthopedic hospital market in Southwest China is highly fragmented and competitive [11]. IPO Fund Utilization - The funds raised from the IPO are intended for upgrading and expanding existing hospital service capabilities, consolidating the company's position in the specialized field [11]. - The company plans to use the funds for mergers, acquisitions, or investments to deepen its "One Elderly, One Child" strategic layout [11]. - Additional allocations will be made for establishing a group research center and introducing advanced medical technologies and smart medical systems [11].